Jiangsu Public TV visit MediLink

2022-10-28Learn more

FDA Clearance of IND Application for YL202

September 3, 2022 - MediLink Therapetutics announced that YL202 has been cleared for its IND application by the U.S. Food and Drug Administration for Phase I first-in-human study

2022-09-03Learn more

1st patient dosed with product YL201 in the United States

2022-04-23Learn more

MediLink Therapeutics closes US$70 million Series B financing

SUZHOU, China, March 14, 2022 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of a US$70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highlight Capital (HLC), etc. The new funding will support clinical development of MediLink's new generation Antibody-Drug Conjugate (ADC) pipeline, as well as early discovery and development of novel conjugated drugs.

2022-04-14Learn more

FDA Clearance of IND Application for YL201

2022-04-12Learn more

MediLink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development

SUZHOU, China, March 1, 2021 /PRNewswire/ -- Suzhou MediLink Therapeutics Ltd. (MediLink), a global biotech company focusing on next-generation antibody-drug conjugate Research & development, announced the closing of a $50 million series A financing, to accelerate its innovative pipeline development and to support its unique conjugate technology platform. The financing includes a series-A1 round led by Apricot Capital, and a series-A2 round co-led by Loyal Valley Capital and Qiming Venture Partners.

2021-03-01Learn more